ADRB3
Beta-3 adrenergic receptor
As of the edition of 20 October 2026, ADRB3 (beta-3 adrenergic receptor, UniProt P13945) has 20 drugs tested at it and 18 companies on the list, 4 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13945
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Nervous system; Digestive system; Lungs and airways; Cancer; Injuries
- Registered trials of its drugs
- 872
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Active | 1 |
| Went quiet | 2 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Total | 20 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Epinephrine | Marketed | Phase 4 | none listed |
| Norepinephrine | Marketed | Phase 4 | none listed |
| Carvedilol | Marketed | Phase 4 | none listed |
| Mirabegron | Marketed | Phase 4 | none listed |
| Ephedrine | Marketed | Phase 4 | none listed |
| Labetalol | Marketed | Phase 4 | none listed |
| Droxidopa | Marketed | Phase 4 | none listed |
| Isoproterenol | Marketed | Phase 4 | none listed |
| Vibegron | Marketed | Phase 3 | Ends 2034 |
| Amibegron | Went quiet | Phase 3 | none listed |
| Levopropranolol | Stopped | Phase 4 | none listed |
| Solabegron | Went quiet | Phase 2 | none listed |
12 of 20 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 5 |
| Engaged | 3 |
| Undetermined | 6 |
| Total on the list | 18 |
The other 15 companies at ADRB3
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at ADRB3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.